PE20081796A1 - Derivados de pirimidina - Google Patents

Derivados de pirimidina

Info

Publication number
PE20081796A1
PE20081796A1 PE2008000392A PE2008000392A PE20081796A1 PE 20081796 A1 PE20081796 A1 PE 20081796A1 PE 2008000392 A PE2008000392 A PE 2008000392A PE 2008000392 A PE2008000392 A PE 2008000392A PE 20081796 A1 PE20081796 A1 PE 20081796A1
Authority
PE
Peru
Prior art keywords
alkyl
ilphenyl
halo
compounds
dimorpholin
Prior art date
Application number
PE2008000392A
Other languages
English (en)
Inventor
Susan Elizabeth Ashton
Darren Anthony Edward Cross
Simon John East
Jason Grant
Mark Andrew Pearson
Stephen Robert Wedge
Bernard Christophe Barlaam
Richard Ducray
Stuart Charles Purkiss
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081796A1 publication Critical patent/PE20081796A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDINA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C4), CICLOALQUILO(C3-C4) O CICLOPROPILMETILO OPCIONALMENTE SUSTITUIDO CON CN, HALO, ENTRE OTROS; n ES DE 0 A 3; R2 ES ALQUILO(C1-C2), ALCOXI(C1-C2), F, Cl, CN, ENTRE OTROS; R3 ES H, HALO, NITRO, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R4 ES NR17R18, EN DONDE R17 Y R18 SE UNEN PARA FORMAR UN ANILLO HETEROCICLICO DE 4, 5, 6 O 7 MIEMBROS OPCIONALMENTE SUSTITUIDO CON OXO, HALO, HIDROXI, CN, ALQUILO(C1-C4), ENTRE OTROS SUSTITUYENTES. SON COMPUESTOS PREFERIDOS: 3-[[2-[(3,5-DIMORFOLIN-4-ILFENIL)AMINO]PIRIMIDIN-4-IL]-METILAMINO]-4-METILFENIL]METANOL, N'-(3-CLORO-2,4-DIFLUOROFENIL)-N'-METIL-N-(3-MORFOLIN-4-IL-5-TIOMORFOLIN-4-ILFENIL)PIRIMIDIN-2,4-DIAMINA, N'-(3-CLORO-2,4-DIFLUOROFENIL)-N-(3,5-DIMORFOLIN-4-ILFENIL)-N'-METILPIRIMIDIN-2,4-DIAMINA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR EphB4 SIENDO UTILES EN EL TRATAMIENTO DE CANCER
PE2008000392A 2007-02-28 2008-02-27 Derivados de pirimidina PE20081796A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07300833 2007-02-28
EP07300832 2007-02-28
EP07300960 2007-04-18
EP07301270 2007-07-24
EP07301269 2007-07-24

Publications (1)

Publication Number Publication Date
PE20081796A1 true PE20081796A1 (es) 2009-02-04

Family

ID=39301133

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000392A PE20081796A1 (es) 2007-02-28 2008-02-27 Derivados de pirimidina

Country Status (7)

Country Link
US (1) US20080242663A1 (es)
EP (1) EP2132184A1 (es)
JP (1) JP2010520187A (es)
AR (1) AR065531A1 (es)
PE (1) PE20081796A1 (es)
TW (1) TW200840581A (es)
WO (1) WO2008104754A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008277446A1 (en) * 2007-07-16 2009-01-22 Astrazeneca Ab Pyrimidine derivatives 934
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
PE20120508A1 (es) 2009-06-17 2012-05-09 Vertex Pharma Inhibidores de la replicacion de los virus de la gripe
JP2013508396A (ja) * 2009-10-23 2013-03-07 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 組成物および方法
CN102858767B (zh) 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
AU2013333938A1 (en) 2012-10-16 2015-04-09 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
SG10201804021TA (en) 2013-11-13 2018-07-30 Vertex Pharma Methods of preparing inhibitors of influenza viruses replication
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
RS64654B1 (sr) 2017-07-28 2023-10-31 Yuhan Corp Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
GB0425035D0 (en) * 2004-11-12 2004-12-15 Novartis Ag Organic compounds
PT1951684T (pt) * 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma

Also Published As

Publication number Publication date
WO2008104754A1 (en) 2008-09-04
EP2132184A1 (en) 2009-12-16
AR065531A1 (es) 2009-06-10
US20080242663A1 (en) 2008-10-02
JP2010520187A (ja) 2010-06-10
TW200840581A (en) 2008-10-16

Similar Documents

Publication Publication Date Title
PE20081796A1 (es) Derivados de pirimidina
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20061067A1 (es) Derivados de pirimidina
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20090417A1 (es) Compuestos de piperazina con accion herbicida
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PE20081662A1 (es) DERIVADOS DE 6-OXO-6,7-DIHIDRO-5H-DIBENZO[b,d]AZEPIN-7-ILO
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20061303A1 (es) Composicion farmaceutica que comprende oxaprozina
PE20081596A1 (es) Derivados fluorinados de deferiprona
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR059138A1 (es) Derivados de 1,2,4-triazol antagonistas de edg-1
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5

Legal Events

Date Code Title Description
FD Application declared void or lapsed